Glenmark Launches Axitinib Authorised Generic in US as Shares Trade Higher
Glenmark Pharmaceuticals has launched an authorised generic of INLYTA in the US in two strengths. The reference brand recorded annual US sales of approximately USD 538.4 million, while Glenmark shares traded higher.
✨ महत्त्वाचे मुद्दे
Glenmark Pharmaceuticals announced on November 16, 2026, that its US subsidiary had launched Axitinib Tablets in 1 mg and 5 mg strengths, an authorised generic version of INLYTA. Shares were trading 0.96 per cent higher in early trade. The launch broadens Glenmark’s US portfolio as the company builds on a recovery in its core North American business.
According to IQVIA sales data cited by Glenmark, INLYTA Tablets recorded approximately USD 538.4 million in US sales during the 12 months ended September 2026. That figure represents sales of the reference brand, rather than revenue attributable to Glenmark’s new product. INLYTA is a trademark of Pfizer Inc.
The launch was undertaken by Glenmark Pharmaceuticals Inc., USA, and disclosed to the National Stock Exchange of India and BSE. Marc Kikuchi, President and Business Head, North America, said the addition reinforced the company’s commitment to expanding access to quality, affordable medicines in the US.
The product joins an increasingly active US launch programme. Glenmark introduced four products during the second quarter of financial year 2026-27, including prescription fluticasone nasal spray. Its latest investor presentation reported core North American business growth of about 31 per cent YoY in the quarter and about 25 per cent in the first half. Respiratory products remain central to that recovery.
Reported financial comparisons require a different reading. Consolidated September-quarter net sales declined 29.76 per cent YoY to Rs 4,247.33 crore, although they rose 5.69 per cent QoQ. Net profit fell to Rs 263.83 crore from Rs 610.43 crore a year earlier. Prior-period recognition of ISB 2001 out-licensing income distorts revenue comparisons, making underlying product sales particularly important when assessing operating momentum.
Glenmark shares traded at Rs 2,680.90 at 9:40 am on November 16, 2026, against a previous close of Rs 2,655.45. The stock had gained 40.98 per cent over one year, compared with a 0.08 per cent decline in the BSE 500 over the supplied comparable period. That sizeable outperformance provides important context, with the latest launch arriving after a substantial appreciation in the share price.
What the Axitinib Launch Adds to Glenmark’s US Recovery
Axitinib adds another commercial product to Glenmark’s US portfolio, supporting the effort to generate growth from recurring medicine sales alongside innovation-led licensing income. The reference brand’s sales indicate a meaningful market, but they should not be treated as Glenmark’s addressable revenue at unchanged prices. Actual contribution will depend on market share, realised pricing and the pace of uptake. Its near-term significance is therefore an additional source of sales rather than evidence of a step-change in group earnings.
For investors, the useful test will be whether successive launches sustain core North American growth while protecting profitability. Generic competition and pricing pressure can limit the value captured from a sizeable brand market. Glenmark also faces higher raw-material, packaging and Logistics costs. Continued product rollout, supply reliability and operating-margin delivery will offer firmer evidence of the recovery’s durability than launch announcements alone.
Disclaimer: The article is for informational purposes only and not investment advice.
